Proceedings of the National Academy of Sciences, India Section B: Biological Sciences Науки об окружающей среде (общие)

^188Re-SIRT Cold Kit: A Promising and Affordable Solution for Hepatocellular Carcinoma

Chopra, Sejal, Kalra, Naveen, Mathur, Yamini, Krishnan, Swathy, Kaur, Komalpreet, Chhabra, Anupriya, Rathore, Yogesh, Bhujade, Harish, Singh, Harmandeep, Kumar, Rajender, Duseja, Ajay, Mittal, Bhagwant Rai, Shukla, Jaya
Springer Nature · 2026-12-01 · DOI 10.1007/s40011-026-01809-w

Аннотация

Selective Intra-arterial Therapy (SIRT) using ^90Y-spheres is a well-established treatment for hepatocellular carcinoma (HCC), but its high cost creates an economic barrier. We present the utility, preliminary therapeutic efficacy, and safety of ^188Re-microspheres SIRT plus sorafenib in prospective interventional study. Sixty patients with Barcelona Clinic Liver Cancer (BCLC) B/C HCC underwent ^188Re-SIRT with 3678 ± 1214 MBq (100 ± 33 mCi) ^188Re-microspheres in combination with sorafenib. Patient characteristics and treatment-related data were collected at baseline; adverse events and time-to-event data (overall survival [OS], progression-free survival [PFS] and hepatic PFS) were collected at every 3-month follow-up visit. Prognostic value of FDG PET/Triple-phase CT (TPCT) was analyzed, comparing modified response evaluation criteria in solid tumors (mRECIST) with positron emission tomograph response criteria in solid tumors (PERCIST) criteria. Cox proportional hazards and Kaplan–Meier analyses were performed to identify prognostic factors affecting preliminary treatment efficacy and survival. Single-point dosimetry was performed using Qthera.AI software. The median OS was 11 months. Qthera.AI estimated mean time integrated activity coefficient for ^188Re-microspheres was 27.0 ± 17.7 h. The mean absorbed doses to tumor, healthy liver, lungs, and spleen were 92.4 Gy, 7.0 Gy, 3.4 Gy, and 21.9 Gy, respectively. Both mRECIST and PERCIST showed comparable median PFS (3.0 months; p=1.000) and extra-hepatic PFS (3.0 months; 0.317), while PERCIST indicated a higher median hepatic PFS (6.0 vs. 3.0 months; 0.655). mRECIST and PERCIST classified 45.0% and 36.7% of patients as responders, respectively. Baseline total lesion glycolysis TLG (Area under curve AUC 0.9, < 0.001) and tumor-to-background ratio TBR (AUC 0.8, 0.043) effectively distinguished responders with cut-offs of 151.2 and 2.2, respectively. Univariate Cox analysis identified ALBI grade (p=0.022), bilirubin (0.009), and pre-SIRT PET parameters (TLG: 0.041, TBR: 0.007) as OS predictors. Multivariate analysis highlighted age (0.049), HCV positivity (0.006), and disease focality (0.043) as significant OS determinants. Post ^188Re-SIRT, 72% of patients experienced grade 1–2 adverse events, decreasing to 38.3% at three months, with significantly improved quality-of-life (p=0.001). ^188Re-SIRT plus sorafenib emerged as a safe, well-tolerated, and cost-effective combination treatment for achieving tumor control in HCC, with no significant adverse events.

Читать у издателя →